Analyst firms · Needham · NEO
Needham NEO price target and rating history
NeoGenomics Inc. (NEO) · Health Care
Needham rates NeoGenomics Inc. (NEO) Buy with a $15 price target, as of its latest action on Feb 1, 2023. It has published 5 rating actions on NEO since November 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $15
- Median target, all firms
- Too few
- Actions on NEO
- 5
Needham price target on NEO
Every Needham rating on NEO
- Feb 1, 2023
- Aug 22, 2022DowngradeNeedham downgrades to Hold from Buy
- Feb 24, 2022
- Dec 7, 2021
- Nov 5, 2021
How other firms rate NEO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BTIG | Buy | $28 | Oct 6, 2026 |
| Leerink Partners | Outperform | $25 | Apr 29, 2026 |
Questions about Needham and NEO
- What is Needham's price target for NEO?
- Needham's latest stated price target for NeoGenomics Inc. (NEO) is $15, from its action on Feb 1, 2023.
- What is Needham's rating on NEO?
- Needham rates NEO Buy, a bullish rating, as of Feb 1, 2023.
- When did Needham last change its view on NEO?
- On Feb 1, 2023, Needham upgrades to Buy from Hold, price target $15.
More NEO rating histories
All Needham ratingsNEO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.